Sildenafil, a phosphodiesterase type 5 inhibitor, enhances the activity of two atypical antidepressant drugs, mianserin and tianeptine, in the forced swim test in mice

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 38, Issue 2, 2012, Pages 121-126

  Socała, Katarzyna ^a   Nieoczym, Dorota ^a   Wyska, Elzbieta ^b   Poleszak, Ewa ^c   Wlaź, Piotr ^a  

^a MARIA CURIE SK ODOWSKA UNIVERSITY   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^c MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Antidepressants; Forced swim test; Mianserin; Sildenafil; Tianeptine

Indexed keywords

ANTIDEPRESSANT AGENT; MIANSERIN; SILDENAFIL; TIANEPTINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG BRAIN LEVEL; DRUG POTENTIATION; FORCED SWIMMING TEST; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LOCOMOTION; MALE; MOUSE; NONHUMAN; PHARMACODYNAMICS;

ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; BRAIN; DRUG SYNERGISM; MALE; MIANSERIN; MICE; MOTOR ACTIVITY; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PURINES; STRESS, PHYSIOLOGICAL; SULFONES; SWIMMING; THIAZEPINES;

EID: 84862881070     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2012.02.013     Document Type: Article

References (75)

1. Ambriz-Tututi M., Velázquez-Zamora D.A., Urquiza-Marín H., Granados-Soto V. Analysis of the mechanism underlying the peripheral antinociceptive action of sildenafil in the formalin test. Eur J Pharmacol 2005, 512:121-127.
2. Asomoza-Espinosa R., Alonso-López R., Mixcoatl-Zecuatl T., Aguirre-Bañuelos P., Torres-López J.E., Granados-Soto V. Sildenafil increases diclofenac antinociception in the formalin test. Eur J Pharmacol 2001, 418:195-200.
3. Balon R. SSRI-associated sexual dysfunction. Am J Psychiatry 2006, 163:1504-1509.
4. Bernstein H.G., Stanarius A., Baumann B., Henning H., Krell D., Danos P., et al. Nitric oxide synthase-containing neurons in the human hypothalamus: reduced number of immunoreactive cells in the paraventricular nucleus of depressive patients and schizophrenics. Neuroscience 1998, 83:867-875.
5. Brink C.B., Harvey B.H., Brand L. Tianeptine: a novel atypical antidepressant that may provide new insights into the biomolecular basis of depression. Recent Pat CNS Drug Discov 2006, 1:29-41.
6. Brink C.B., Clapton J.D., Eagar B.E., Harvey B.H. Appearance of antidepressant-like effect by sildenafil in rats after central muscarinic receptor blockade: evidence from behavioural and neuro-receptor studies. J Neural Transm 2008, 115:117-125.
7. Caccia S. Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications. Clin Pharmacokinet 1998, 34:281-302.
8. Chrapko W.E., Jurasz P., Radomski M.W., Lara N., Archer S.L., Le Melledo J.M. Decreased platelet nitric oxide synthase activity and plasma nitric oxide metabolites in major depressive disorder. Biol Psychiatry 2004, 56:129-134.
9. Chrapko W., Jurasz P., Radomski M.W., Archer S.L., Newman S.C., Baker G., et al. Alteration of decreased plasma NO metabolites and platelet NO synthase activity by paroxetine in depressed patients. Neuropsychopharmacology 2006, 31:1286-1293.
10. Corbin J.D., Francis S.H. Cyclic GMP phosphodiesterase-5: target of sildenafil. J Biol Chem 1999, 274:13729-13732.
11. da Silva G.D., Matteussi A.S., dos Santos A.R., Calixto J.B., Rodrigues A.L. Evidence for dual effects of nitric oxide in the forced swimming test and in the tail suspension test in mice. Neuroreport 2000, 11:3699-3702.
12. Devan B.D., Sierra-Mercado D., Jimenez M., Bowker J.L., Duffy K.B., Spangler E.L., et al. Phosphodiesterase inhibition by sildenafil citrate attenuates the learning impairment induced by blockade of cholinergic muscarinic receptors in rats. Pharmacol Biochem Behav 2004, 79:691-699.
13. Dhir A., Kulkarni S.K. Involvement of l-arginine-nitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effect of venlafaxine in mice. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:921-925.
14. Dhir A., Kulkarni S.K. Involvement of nitric oxide (NO) signaling pathway in the antidepressant action of bupropion, a dopamine reuptake inhibitor. Eur J Pharmacol 2007, 568:177-185.
15. Eroglu L., Caglayan B. Anxiolytic and antidepressant properties of methylene blue in animal models. Pharmacol Res 1997, 36:381-385.
16. Esplugues J.V. NO as a signalling molecule in the nervous system. Br J Pharmacol 2002, 135:1079-1095.
17. Getting S.J., Segieth J., Ahmad S., Biggs C.S., Whitton P.S. Biphasic modulation of GABA release by nitric oxide in the hippocampus of freely moving rats in vivo. Brain Res 1996, 717:196-199.
18. Ghofrani H.A., Osterloh I.H., Grimminger F. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov 2006, 5:689-702.
19. Golds P.R., Przyslo F.R., Strange P.G. The binding of some antidepressant drugs to brain muscarinic acetylcholine receptors. Br J Pharmacol 1980, 68:541-549.
20. Harkin A.J., Bruce K.H., Craft B., Paul I.A. Nitric oxide synthase inhibitors have antidepressant-like properties in mice. 1. Acute treatments are active in the forced swim test. Eur J Pharmacol 1999, 372:207-213.
21. Harkin A., Connor T.J., Walsh M., St John N., Kelly J.P. Serotonergic mediation of the antidepressant-like effects of nitric oxide synthase inhibitors. Neuropharmacology 2003, 44:616-623.
22. Harkin A., Connor T.J., Burns M.P., Kelly J.P. Nitric oxide synthase inhibitors augment the effects of serotonin re-uptake inhibitors in the forced swimming test. Eur Neuropsychopharmacol 2004, 14:274-281.
23. Harvey B.H., Duvenhage I., Viljoen F., Scheepers N., Malan S.F., Wegener G., et al. Role of monoamine oxidase, nitric oxide synthase and regional brain monoamines in the antidepressant-like effects of methylene blue and selected structural analogues. Biochem Pharmacol 2010, 80:1580-1591.
24. Heiberg I.L., Wegener G., Rosenberg R. Reduction of cGMP and nitric oxide has antidepressant-like effects in the forced swimming test in rats. Behav Brain Res 2002, 134:479-484.
25. Hyland R., Roe E.G., Jones B.C., Smith D.A. Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil. Br J Clin Pharmacol 2001, 51:239-248.
26. Inan S.Y., Yalcin I., Aksu F. Dual effects of nitric oxide in the mouse forced swimming test: possible contribution of nitric oxide-mediated serotonin release and potassium channel modulation. Pharmacol Biochem Behav 2004, 77:457-464.
27. Jackson G., Gillies H., Osterloh I. Past, present, and future: a 7-year update of Viagra (sildenafil citrate). Int J Clin Pract 2005, 59:680-691.
28. Jain N.K., Patil C.S., Singh A., Kulkarni S.K. Sildenafil-induced peripheral analgesia and activation of the nitric oxide-cyclic GMP pathway. Brain Res 2001, 909:170-178.
29. Jain N.K., Patil C.S., Singh A., Kulkarni S.K. Sildenafil, a phosphodiesterase-5 inhibitor, enhances the antinociceptive effect of morphine. Pharmacology 2003, 67:150-156.
30. Kaehler S.T., Singewald N., Sinner C., Philippu A. Nitric oxide modulates the release of serotonin in the rat hypothalamus. Brain Res 1999, 835:346-349.
31. Kulkarni S.K., Dhir A. Effect of various classes of antidepressants in behavioral paradigms of despair. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:1248-1254.
32. Liebenberg N., Wegener G., Harvey B.H., Brink C.B. Investigating the role of protein kinase-G in the antidepressant-like response of sildenafil in combination with muscarinic acetylcholine receptor antagonism. Behav Brain Res 2010, 209:137-141.
33. Lorrain D.S., Hull E.M. Nitric oxide increases dopamine and serotonin release in the medial preoptic area. Neuroreport 1993, 5:87-89.
34. Mantovani M., Pértile R., Calixto J.B., Santos A.R., Rodrigues A.L. Melatonin exerts an antidepressant-like effect in the tail suspension test in mice: evidence for involvement of N-methyl-d-aspartate receptors and the l-arginine-nitric oxide pathway. Neurosci Lett 2003, 343:1-4.
35. McEwen B.S., Chattarji S., Diamond D.M., Jay T.M., Reagan L.P., Svenningsson P., et al. The neurobiological properties of tianeptine (Stablon): from monoamine hypothesis to glutamatergic modulation. Mol Psychiatry 2010, 15:237-249.
36. Millan M.J. Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther 2006, 110:135-370.
37. Millan M.J., Dekeyne A. Discriminative stimulus properties of the selective norepinephrine reuptake inhibitor, reboxetine, in rats: a characterization with alpha/beta-adrenoceptor subtype selective ligands, antidepressants, and antagonists at neuropeptide receptors. Int J Neuropsychopharmacol 2007, 10:579-593.
38. Nakagawa Y., Ishima T., Takashima T. The 5-HT3 receptor agonist attenuates the action of antidepressants in the forced swim test in rats. Brain Res 1998, 786:189-193.
39. Nieoczym D., Socała K., Wlaź P. Lack of effect of sildenafil on cocaine-induced convulsions in mice. Pharmacol Rep 2009, 61:930-934.
40. Nieoczym D., Socała K., Rundfeldt C., Wlaź P. Effects of sildenafil on pentylenetetrazol-induced convulsions in mice and amygdala-kindled seizures in rats. Pharmacol Rep 2010, 62:383-391.
41. Nurnberg H.G., Hensley P.L. Sildenafil citrate for the management of antidepressant-associated erectile dysfunction. J Clin Psychiatry 2003, 64(Suppl. 10):20-25.
42. Nurnberg H.G., Hensley P.L., Gelenberg A.J., Fava M., Lauriello J., Paine S. Treatment of antidepressant-associated sexual dysfunction with sildenafil: a randomized controlled trial. J Am Med Assoc 2003, 289:56-64.
43. Nurnberg H.G., Fava M., Gelenberg A.J., Hensley P.L., Paine S. Open-label sildenafil treatment of partial and non-responders to double-blind treatment in men with antidepressant-associated sexual dysfunction. Int J Impot Res 2007, 19:167-175.
44. Papakostas G.J., Fava M. Monoaminergic-based pharmacotherapy for depression. Biology of depression: From novel insights to therapeutic strategies 2005, Viley-VCH Verlag, Weinheim. J. Licino, M.L. Wong (Eds.).
45. Patil C.S., Jain N.K., Singh V.P., Kulkarni S.K. Cholinergic-NO-cGMP mediation of sildenafil-induced antinociception. Indian J Exp Biol 2004, 42:361-367.
46. Poleszak E. Modulation of antidepressant-like activity of magnesium by serotonergic system. J Neural Transm 2007, 114:1129-1134.
47. Porsolt R.D., Bertin A., Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 1977, 229:327-336.
48. Prast H., Philippu A. Nitric oxide as modulator of neuronal function. Prog Neurobiol 2001, 64:51-68.
49. Prast H., Lamberti C., Fischer H., Tran M.H., Philippu A. Nitric oxide influences the release of histamine and glutamate in the rat hypothalamus. Naunyn-Schmiedebergs Arch Pharmacol 1996, 354:731-735.
50. Preskorn S.H. Tianeptine: a facilitator of the reuptake of serotonin and norepinephrine as an antidepressant?. J Psychiatr Pract 2004, 10:323-330.
51. Prickaerts J., van Staveren W.C., Sik A., Markerink-van Ittersum M., Niewohner U., van der Staay F.J., et al. Effects of two selective phosphodiesterase type 5 inhibitors, sildenafil and vardenafil, on object recognition memory and hippocampal cyclic GMP levels in the rat. Neuroscience 2002, 113:351-361.
52. Prickaerts J., Sik A., van Staveren W.C., Koopmans G., Steinbusch H.W., van der Staay F.J., et al. Phosphodiesterase type 5 inhibition improves early memory consolidation of object information. Neurochem Int 2004, 45:915-928.
53. Puerta E., Hervias I., Goñi-Allo B., Lasheras B., Jordan J., Aguirre N. Phosphodiesterase 5 inhibitors prevent 3,4-methylenedioxymethamphetamine-induced 5-HT deficits in the rat. J Neurochem 2009, 108:755-766.
54. Puerta E., Hervias I., Barros-Miñones L., Jordan J., Ricobaraza A., Cuadrado-Tejedor M., et al. Sildenafil protects against 3-nitropropionic acid neurotoxicity through the modulation of calpain, CREB, and BDNF. Neurobiol Dis 2010, 38:237-245.
55. Rosen R.C., McKenna K.E. PDE-5 inhibition and sexual response: pharmacological mechanisms and clinical outcomes. Annu Rev Sex Res 2002, 13:36-88.
56. Rutten K., Vente J.D., Sik A., Ittersum M.M., Prickaerts J., Blokland A. The selective PDE5 inhibitor, sildenafil, improves object memory in Swiss mice and increases cGMP levels in hippocampal slices. Behav Brain Res 2005, 164:11-16.
57. Schultheiss D., Muller S.V., Nager W., Stief C.G., Schlote N., Jonas U., et al. Central effects of sildenafil (Viagra) on auditory selective attention and verbal recognition memory in humans: a study with event-related brain potentials. World J Urol 2001, 19:46-50.
58. Segovia G., Porras A., Mora F. Effects of a nitric oxide donor on glutamate and GABA release in striatum and hippocampus of the conscious rat. Neuroreport 1994, 5:1937-1940.
59. Seidman S.N., Roose S.P., Menza M.A., Shabsigh R., Rosen R.C. Treatment of erectile dysfunction in men with depressive symptoms: results of a placebo-controlled trial with sildenafil citrate. Am J Psychiatry 2001, 158:1623-1630.
60. Shi Z., Tiwari A.K., Shukla S., Robey R.W., Singh S., Kim I.W., et al. Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance. Cancer Res 2011, 71:3029-3041.
61. Socała K., Nieoczym D., Wyska E., Poleszak E., Wlaź P., Sildenafil a phosphodiesterase type 5 inhibitor, enhances the antidepressant activity of amitriptyline but not desipramine, in the forced swim test in mice. J Neural Transm 2012, 10.1007/s00702-011-0756-9.
62. Spina E., Santoro V., D'Arrigo C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther 2008, 30:1206-1227.
63. Strasser A., McCarron R.M., Ishii H., Stanimirovic D., Spatz M. l-arginine induces dopamine release from the striatum in vivo. Neuroreport 1994, 5:2298-2300.
64. Sugimoto Y., Yamada S., Yamada J. The 5-HT2 receptor antagonist reduces immobility of mice treated with the atypical antidepressant mianserin in the forced swimming test. Biol Pharm Bull 2002, 25:1479-1481.
65. Uthayathas S., Karuppagounder S.S., Thrash B.M., Parameshwaran K., Suppiramaniam V., Dhanasekaran M. Versatile effects of sildenafil: recent pharmacological applications. Pharmacol Rep 2007, 59:150-163.
66. Uzbay T.I. Tianeptine: potential influences on neuroplasticity and novel pharmacological effects. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:915-924.
67. Vulliemoz Y., Shen H., Virag L. Alpha-2 adrenoceptor agonists decrease cyclic guanosine 3',5'-monophosphate in the mouse brain. Anesthesiology 1996, 85:544-550.
68. Wang L., Gang Z.Z., Lan Z.R., Chopp M. Activation of the PI3-K/Akt pathway mediates cGMP enhanced-neurogenesis in the adult progenitor cells derived from the subventricular zone. J Cereb Blood Flow Metab 2005, 25:1150-1158.
69. Wegener G., Bandpey Z., Heiberg I.L., Mørk A., Rosenberg R. Increased extracellular serotonin level in rat hippocampus induced by chronic citalopram is augmented by subchronic lithium: neurochemical and behavioural studies in the rat. Psychopharmacology 2003, 166:188-194.
70. Yildiz F., Erden B.F., Ulak G., Utkan T., Gacar N. Antidepressant-like effect of 7-nitroindazole in the forced swimming test in rats. Psychopharmacology 2000, 149:41-44.
71. Zhang R., Wang Y., Zhang L., Zhang Z., Tsang W., Lu M., et al. Sildenafil (Viagra) induces neurogenesis and promotes functional recovery after stroke in rats. Stroke 2002, 33:2675-2680.
72. Zhang L., Zhang R.L., Wang Y., Zhang C., Zhang Z.G., Meng H., et al. Functional recovery in aged and young rats after embolic stroke: treatment with a phosphodiesterase type 5 inhibitor. Stroke 2005, 36:847-852.
73. Zhang R.L., Zhang Z., Zhang L., Wang Y., Zhang C., Chopp M. Delayed treatment with sildenafil enhances neurogenesis and improves functional recovery in aged rats after focal cerebral ischemia. J Neurosci Res 2006, 83:1213-1219.
74. Zhu C.B., Hewlett W.A., Francis S.H., Corbin J.D., Blakely R.D. Stimulation of serotonin transport by the cyclic GMP phosphodiesterase-5 inhibitor sildenafil. Eur J Pharmacol 2004, 504:1-6.
75. Zomkowski A.D., Engel D., Gabilan N.H., Rodrigues A.L. Involvement of NMDA receptors and l-arginine-nitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effects of escitalopram in the forced swimming test. Eur Neuropsychopharmacol 2010, 20:793-801.